Comparison of the response of frequently relapsing steroid-dependent minimal change nephrotic syndrome to rituximab therapy between childhood-onset and adult-onset disease

Rituximab has been approved in Japan for the treatment of intractable nephrotic syndrome, but in cases of childhood-onset disease only; its efficacy and safety in adult-onset disease has yet to be established. This study was undertaken to evaluate the efficacy of rituximab and adverse effects in pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Iwabuchi, Yuko, Miyabe, Yoei, Makabe, Shiho, Nakano, Marie, Manabe, Shun, Karasawa, Kazunori, Moriyama, Takahito, Nitta, Kosaku
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6211879/
https://www.ncbi.nlm.nih.gov/pubmed/30334956
http://dx.doi.org/10.1097/MD.0000000000012704

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6211879/
https://www.ncbi.nlm.nih.gov/pubmed/30334956
http://dx.doi.org/10.1097/MD.0000000000012704

Ejemplares similares